A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
27 Apr 2019
Historique:
received: 01 11 2018
accepted: 12 04 2019
entrez: 29 4 2019
pubmed: 29 4 2019
medline: 20 6 2019
Statut: epublish

Résumé

Cervical cancer is caused by oncogenic human papillomaviruses (HPV) and is one of the most common malignancies in women living in sub-Saharan Africa. Women infected with the human immunodeficiency virus (HIV) have a higher incidence of cervical cancer, but the full impact on HPV detection is not well understood, and associations of biological and behavioral factors with oncogenic HPV detection have not been fully examined. Therefore, a study was initiated to investigate factors that are associated with oncogenic HPV detection in Kenyan women. Women without cervical dysplasia were enrolled in a longitudinal study. Data from enrollment are presented as a cross-sectional analysis. Demographic and behavioral data was collected, and HPV typing was performed on cervical swabs. HIV-uninfected women (n = 105) and HIV-infected women (n = 115) were compared for demographic and behavioral characteristics using t-tests, Chi-square tests, Wilcoxon sum rank tests or Fisher's exact tests, and for HPV detection using logistic regression or negative binomial models adjusted for demographic and behavioral characteristics using SAS 9.4 software. Compared to HIV-uninfected women, HIV-infected women were older, had more lifetime sexual partners, were less likely to be married, were more likely to regularly use condoms, and were more likely to have detection of HPV 16, other oncogenic HPV types, and multiple oncogenic types. In addition to HIV, more lifetime sexual partners was associated with a higher number of oncogenic HPV types (aIRR 1.007, 95% CI 1.007-1.012). Greater travel distance to the clinic was associated with increased HPV detection (aOR for detection of ≥ 2 HPV types: 3.212, 95% CI 1.206-8.552). Older age (aOR for HPV 16 detection: 0.871, 95% CI 0.764-0.993) and more lifetime pregnancies (aOR for detection of oncogenic HPV types: 0.706, 95% CI, 0.565-0.883) were associated with reduced detection. HIV infection, more lifetime sexual partners, and greater distance to health-care were associated with a higher risk of oncogenic HPV detection, in spite of ART use in those who were HIV-infected. Counseling of women about sexual practices, improved access to health-care facilities, and vaccination against HPV are all potentially important in reducing oncogenic HPV infections.

Sections du résumé

BACKGROUND BACKGROUND
Cervical cancer is caused by oncogenic human papillomaviruses (HPV) and is one of the most common malignancies in women living in sub-Saharan Africa. Women infected with the human immunodeficiency virus (HIV) have a higher incidence of cervical cancer, but the full impact on HPV detection is not well understood, and associations of biological and behavioral factors with oncogenic HPV detection have not been fully examined. Therefore, a study was initiated to investigate factors that are associated with oncogenic HPV detection in Kenyan women.
METHODS METHODS
Women without cervical dysplasia were enrolled in a longitudinal study. Data from enrollment are presented as a cross-sectional analysis. Demographic and behavioral data was collected, and HPV typing was performed on cervical swabs. HIV-uninfected women (n = 105) and HIV-infected women (n = 115) were compared for demographic and behavioral characteristics using t-tests, Chi-square tests, Wilcoxon sum rank tests or Fisher's exact tests, and for HPV detection using logistic regression or negative binomial models adjusted for demographic and behavioral characteristics using SAS 9.4 software.
RESULTS RESULTS
Compared to HIV-uninfected women, HIV-infected women were older, had more lifetime sexual partners, were less likely to be married, were more likely to regularly use condoms, and were more likely to have detection of HPV 16, other oncogenic HPV types, and multiple oncogenic types. In addition to HIV, more lifetime sexual partners was associated with a higher number of oncogenic HPV types (aIRR 1.007, 95% CI 1.007-1.012). Greater travel distance to the clinic was associated with increased HPV detection (aOR for detection of ≥ 2 HPV types: 3.212, 95% CI 1.206-8.552). Older age (aOR for HPV 16 detection: 0.871, 95% CI 0.764-0.993) and more lifetime pregnancies (aOR for detection of oncogenic HPV types: 0.706, 95% CI, 0.565-0.883) were associated with reduced detection.
CONCLUSION CONCLUSIONS
HIV infection, more lifetime sexual partners, and greater distance to health-care were associated with a higher risk of oncogenic HPV detection, in spite of ART use in those who were HIV-infected. Counseling of women about sexual practices, improved access to health-care facilities, and vaccination against HPV are all potentially important in reducing oncogenic HPV infections.

Identifiants

pubmed: 31029097
doi: 10.1186/s12879-019-3982-7
pii: 10.1186/s12879-019-3982-7
pmc: PMC6487004
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

352

Subventions

Organisme : NCI NIH HHS
ID : U54 CA190151
Pays : United States
Organisme : National Institutes of Health
ID : 5U54CA190151-05.

Références

N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
J Natl Cancer Inst Monogr. 2003;(31):3-13
pubmed: 12807939
J Infect Dis. 2005 Jan 15;191(2):182-92
pubmed: 15609227
AIDS. 2006 Nov 28;20(18):2337-44
pubmed: 17117020
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636
pubmed: 18354839
Acta Cytol. 2009 Jan-Feb;53(1):10-7
pubmed: 19248549
AIDS. 2011 Feb 20;25(4):463-71
pubmed: 21139489
J Infect Dis. 2011 Feb 15;203(4):479-86
pubmed: 21216869
J Natl Cancer Inst. 2011 Jun 22;103(12):918-9
pubmed: 21693755
Br J Cancer. 2012 Oct 23;107(9):1624-30
pubmed: 23033006
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955
Vaccine. 2012 Nov 20;30 Suppl 5:F168-74
pubmed: 23199960
PLoS One. 2013;8(1):e55383
pubmed: 23383171
Front Oncol. 2014 Mar 14;4:48
pubmed: 24672770
J Acquir Immune Defic Syndr. 2014 May 1;66 Suppl 1:S130-7
pubmed: 24732817
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Curr Opin HIV AIDS. 2017 Jan;12(1):6-11
pubmed: 27749369
AIDS. 2017 Jan 14;31(2):273-285
pubmed: 27755107
Lancet. 2017 Feb 25;389(10071):847-860
pubmed: 27814965
Clin Infect Dis. 2017 May 1;64(9):1228-1235
pubmed: 28199532
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
BMJ Open. 2017 Aug 4;7(8):e015123
pubmed: 28780541
Lancet HIV. 2018 Jan;5(1):e45-e58
pubmed: 29107561
Papillomavirus Res. 2018 Jun;5:75-79
pubmed: 29355777
BMJ Open. 2018 Jan 27;8(1):e019894
pubmed: 29374678
AIDS. 2018 Apr 24;32(7):851-860
pubmed: 29424778
J Infect Dis. 2018 Apr 23;217(10):1544-1552
pubmed: 29452366
Virol J. 2018 Feb 17;15(1):36
pubmed: 29454382
J AIDS HIV Res. 2017 Oct;9(10):202-206
pubmed: 29707404
J Prev Med Hyg. 2017 Dec 30;58(4):E259-E265
pubmed: 29707656
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Vaccine. 2018 Nov 12;36(46):7025-7032
pubmed: 30297124
Gynecol Oncol. 1998 Mar;68(3):233-9
pubmed: 9570972
J Med Virol. 1998 Oct;56(2):133-7
pubmed: 9746069

Auteurs

A Ermel (A)

Indiana University School of Medicine, Indianapolis, IN, USA.

P Tonui (P)

Indiana University School of Medicine, Indianapolis, IN, USA.

M Titus (M)

Maseno University, Kisumu, Kenya.

Y Tong (Y)

Indiana University School of Medicine, Indianapolis, IN, USA.

N Wong (N)

Indiana University School of Medicine, Indianapolis, IN, USA.

J Ong'echa (J)

Kenya Medical Research Institute, Nairobi, Kenya.

K Muthoka (K)

Moi University, Eldoret, Kenya.

S Kiptoo (S)

Moi University, Eldoret, Kenya.

A Moormann (A)

University of Massachusetts Medical School, Worcester, MA, USA.

J Hogan (J)

Brown University, Providence, RI, USA.

A Mwangi (A)

Moi University, Eldoret, Kenya.

S Cu-Uvin (S)

Brown University, Providence, RI, USA.

P J Loehrer (PJ)

Indiana University School of Medicine, Indianapolis, IN, USA.

O Orang'o (O)

Moi University, Eldoret, Kenya.

D Brown (D)

Indiana University School of Medicine, Indianapolis, IN, USA. darbrow@iu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH